NASDAQ:SCMP - Sucampo Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$18.00 0.00 (0.00 %)
(As of 03/26/2019 04:00 PM ET)
Previous Close$18.00
Today's Range$18.00 - $18.00
52-Week Range$9.30 - $18.75
Average Volume2.56 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product. VTS-270 is an investigational drug under clinical study for the treatment of Niemann-Pick Disease Type C-1, an ultra-orphan, progressive and fatal disease. AMITIZA is a ClC-2 chloride channel activator, which has been approved for three indications that cover distinct patient types: chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation. RESCULA is a Big Potassium channel activator used to lower intraocular pressure. CPP-1X/sulindac combination product is meant for the treatment of familial adenomatous polyposis (FAP).

Receive SCMP News and Ratings via Email

Sign-up to receive the latest news and ratings for SCMP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:SCMP



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Sucampo Pharmaceuticals (NASDAQ:SCMP) Frequently Asked Questions

What is Sucampo Pharmaceuticals' stock symbol?

Sucampo Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCMP."

How were Sucampo Pharmaceuticals' earnings last quarter?

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) announced its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, beating analysts' consensus estimates of $0.25 by $0.02. The biopharmaceutical company earned $61.27 million during the quarter, compared to analyst estimates of $58.05 million. The company's revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.30 EPS. View Sucampo Pharmaceuticals' Earnings History.

Has Sucampo Pharmaceuticals been receiving favorable news coverage?

News coverage about SCMP stock has been trending negative on Tuesday, InfoTrie reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sucampo Pharmaceuticals earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.

What other stocks do shareholders of Sucampo Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sucampo Pharmaceuticals investors own include XOMA (XOMA), Sprint (S), Teekay Tankers (TNK), Gilead Sciences (GILD), Opko Health (OPK), Canopy Growth (CGC), Alnylam Pharmaceuticals (ALNY), Synergy Pharmaceuticals (SGYP), Alibaba Group (BABA) and ZIOPHARM Oncology (ZIOP).

Who are Sucampo Pharmaceuticals' key executives?

Sucampo Pharmaceuticals' management team includes the folowing people:
  • Peter S. Greenleaf, Chairman of the Board, Chief Executive Officer (Age 47)
  • Peter P. Pfreundschuh CPA, Chief Financial Officer (Age 48)
  • Max Donley, Executive Vice President of Global Human Resources, Information Technology and Strategy (Age 48)
  • Matthias Alder, Executive Vice President (Age 52)
  • Peter A. Kiener Ph.D., Chief Scientific Officer (Age 64)
  • Alex Driggs, General Counsel, Corporate Secretary (Age 41)
  • Peter Lichtlen M.D., Ph.D., Chief Medical Officer (Age 47)
  • John H. Johnson, Lead Independent Director (Age 58)
  • Paul R. Edick, Director (Age 62)
  • Daniel P. Getman Ph.D., Director (Age 59)

How do I buy shares of Sucampo Pharmaceuticals?

Shares of SCMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sucampo Pharmaceuticals' stock price today?

One share of SCMP stock can currently be purchased for approximately $18.00.

What is Sucampo Pharmaceuticals' official website?

The official website for Sucampo Pharmaceuticals is

How can I contact Sucampo Pharmaceuticals?

Sucampo Pharmaceuticals' mailing address is 805 King Farm Blvd Ste 550, ROCKVILLE, MD 20850-6162, United States. The biopharmaceutical company can be reached via phone at +1-301-9613400 or via email at [email protected]

MarketBeat Community Rating for Sucampo Pharmaceuticals (NASDAQ SCMP)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  285 (Vote Outperform)
Underperform Votes:  265 (Vote Underperform)
Total Votes:  550
MarketBeat's community ratings are surveys of what our community members think about Sucampo Pharmaceuticals and other stocks. Vote "Outperform" if you believe SCMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/26/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel